Yduqs Jumps 8.6% on Afya Merger Deal, but Does a R$9.4 Billion Education Giant Face an Antitrust Wall?
Shares of Yduqs surged 8.6% to BRL 12.03 as the market digested the full implications of its binding merger with Afya, Brazil's leading medical-school operator. The all-stock deal, signed September 23, would create one of Latin America's largest private education platforms — but investors betting on a smooth path to closing must reckon with a Brazilian antitrust body that has killed a nearly identical combination before.
A R$9.4 Billion Revenue Giant With Medicine at Its Core. The combined company would serve roughly 1.6 million students, generate combined net revenue of R$9.4 billion and adjusted EBITDA of about R$3.6 billion.
The new group would control approximately 5,888 authorized medical-school seats, with the premium segment — mainly medical education — expected to account for 55% of net revenue and roughly two-thirds of EBITDA. That tilt toward high-margin medical programs is the deal's strategic prize: it turns Yduqs from a broad-based university operator into a predominantly premium education company.
Yduqs Shareholders Get the Smaller Slice — but Analysts Like Their Side. The exchange ratio gives Afya holders 69% and existing Yduqs shareholders 31% of the combined company, with Germany's Bertelsmann emerging as the controlling shareholder at 47.4%. Despite the dilution, the analyst consensus is that the deal favors Yduqs shareholders when measured by synergies, operational gains and dividend-distribution potential.
The companies estimate net-present-value synergies of R$2 billion to R$2.2 billion, after integration costs and taxes.
Brazil's Antitrust Authority Has Blocked This Movie Before. CADE, Brazil's competition regulator, has stopped an education mega-merger before — in 2017 it blocked Kroton's purchase of Estácio (which later became Yduqs).
That earlier deal was rejected by a 5-to-1 vote on concerns about excessive market concentration. The Afya-Yduqs combination will face overlap scrutiny in medical and distance-learning seats. Break-up fees escalate from R$325 million before shareholder votes to R$650 million afterward — real money that signals both parties see regulatory risk as non-trivial.
The Clock Is Ticking Until 2028. The deal's outside closing date is March 31, 2028, subject to extensions.
Post-merger leverage would sit at roughly 1.2× net debt to EBITDA — comfortable, but any CADE-mandated divestitures could alter the economics. Today's rally prices in optimism; the hard work of regulatory clearance lies ahead.